Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UK kidney cancer patients face toxic, out-dated treatments with little hope of change if NICE has its way

09.12.2008
Leading oncologist Professor Tim Eisen has expressed concerns that patients with advanced kidney cancer could be condemned to toxic, barely effective, 20 year-old treatments because the National Institute for Health and Clinical Excellence (NICE) is likely to rule out using all four of the new treatments it has assessed.

Writing in the December issue of BJU International, Professor Eisen, from the University of Cambridge, points out that although NICE has put its findings out for consultation, its provisional decision is that sunitinib, sorafenib, temsirolimus and interferon plus bevacizumab are too costly.

A further review is due to be carried out in January 2009, but Professor Eisen fears that NICE - which advises the UK Department of Health - may confirm its provisional advice that none of these treatments should be provided by the UK’s National Health Service.

“We had hoped that NICE would approve at least one of these drugs, as they represent a major breakthrough and there are no suitable alternatives for the large majority of the 4,000 or so patients who might be considered for these drugs in the UK” says Professor Eisen.

“Given that sunitinib was investigated as a first line option, it seemed most likely that it would be approved.

“Our hopes were dashed when NICE released its consultation document. It said that although the four drugs they looked at were clinically effective, they were not cost-effective.”

Professor Eisen says that about one in ten patients benefit significantly from existing drugs to activate the immune system, leaving the other 90 per cent with no benefits, just a range of unpleasant side effects, including flu-like symptoms and depression.

He points out that a number of very effective treatments have been developed in the last three years, but he fears that when NICE issues its final recommendations next spring the hopes of UK clinicians and patients could be well and truly dashed.

For example sunitinib has already been adopted in advanced Western countries as the first-line therapy for patients who show no indication that they will react adversely to the drug.

However, Professor Eisen stresses that although the data on these new drugs is extremely encouraging, and represents the first major breakthrough in advanced kidney cancer in the last 25 years, none of them will cure the condition. But they can extend a patient’s life. In the case of sunitinib, some patients have had their life expectancy doubled, giving them an extra year.

Professor Eisen says that the predicted outcome of the NICE consultation is depressing for a number of reasons.

“First, if an intervention which doubles progression-free and overall survival in a disease where nothing else works is deemed to be cost-ineffective, the chances of introducing any new cancer medication must be deemed remote. The prospect is that patients treated within the UK National Health Service must wait until therapies are off-patent and therefore become cheaper.

“Second, the NICE cost-effectiveness analysis is at variance with other cost-effectiveness analyses conducted in the USA, Sweden and other countries. In the media furore that greeted NICE’s provisional decision there is no indication that the significant differences between the cost-effectiveness analyses from the UK and elsewhere had caused any pause for thought among the authorities.

“Third, the very great variability of the natural history of kidney cell carcinoma was not considered by NICE. From what we know of these medications already, a minority of patients can benefit very significantly.

“Finally, no provision is made for the importance of gaining even a few months of extra life for patients, despite the fact that these benefits are deemed to be extremely important by all patient groups.”

Professor Eisen concludes that if the NHS is ever to introduce the benefits of novel targeted therapies, except in a very few circumstances such as herceptin in breast cancer, it must reconsider its assessment methods.

“Most doctors accept that however many resources are put into healthcare there will always be a need to ration new and expensive treatments” he says. “Equally, this realisation is spreading to all Western countries and NICE is being closely watched as a forerunner of control mechanisms elsewhere.

“The stark differences in options available for patients in the NHS and most other Western countries suggest that no internationally agreed model is possible at present. The development of an internationally validated tool to assess cost-effectiveness would allow for reliable comparisons of healthcare provision in different countries. Embedding the cost-effectiveness analyses into the pivotal clinical trials would reduce the unacceptable delays in reaching even a provisional decision for patients within the NHS.

“Condemning these kidney cancer patients to toxic, barely effective 20-year old treatment should not be an acceptable option.”

Annette Whibley | alfa
Further information:
http://www.bjui.org

More articles from Health and Medicine:

nachricht Collagen nanofibrils in mammalian tissues get stronger with exercise
14.12.2018 | University of Illinois College of Engineering

nachricht New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Data use draining your battery? Tiny device to speed up memory while also saving power

14.12.2018 | Power and Electrical Engineering

Tangled magnetic fields power cosmic particle accelerators

14.12.2018 | Physics and Astronomy

In search of missing worlds, Hubble finds a fast evaporating exoplanet

14.12.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>